Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation
Joint Authors
Hur, Dae Young
Kim, Kyung Eun
Park, Sunyoung
Cheon, Soyoung
Kim, Dong Yeon
Cho, Dae Jin
Park, Jeong Min
Park, Hyun Jeong
Cho, Daeho
Source
Journal of Immunology Research
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-12-31
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Radotinib (Supect™) was developed to treat chronic myeloid leukemia (CML) as a BCR-ABL1 tyrosine kinase inhibitor (TKI).
Other TKIs, including imatinib and nilotinib, were also developed for treatment of CML, and recent studies were increasing about the therapeutic effects of other TKIs on solid tumors.
However, the effect of radotinib on solid tumors has not yet been investigated.
In this study, radotinib killed CML cell line K562 directly; however, radotinib did not enhance NK cell cytotoxicity against K562 cells.
Because K562 is known as a Fas-negative cell line, we investigated whether radotinib could regulate cell cytotoxicity against various Fas-expressing solid cancer cell lines.
Radotinib dramatically increased NK cell cytotoxicity against various Fas-expressing solid cancer cells, including lung, breast, and melanoma cells.
Additionally, the efficiency of radotinib-enhanced cytotoxicity was lower in Fas siRNA-transfected cells than in negative controls, suggesting that Fas signaling might be involved in the radotinib-enhanced NK cell cytotoxicity.
This study provides the first evidence that radotinib could be used as an effective and strong therapeutic to treat solid tumors via upregulation of NK cell cytotoxicity, suggesting that radotinib has indirect killing mechanisms via upregulation of antitumor innate immune responses as well as direct killing activities for CML cells.
American Psychological Association (APA)
Kim, Kyung Eun& Park, Sunyoung& Cheon, Soyoung& Kim, Dong Yeon& Cho, Dae Jin& Park, Jeong Min…[et al.]. 2018. Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation. Journal of Immunology Research،Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1193339
Modern Language Association (MLA)
Kim, Kyung Eun…[et al.]. Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation. Journal of Immunology Research No. 2018 (2018), pp.1-7.
https://search.emarefa.net/detail/BIM-1193339
American Medical Association (AMA)
Kim, Kyung Eun& Park, Sunyoung& Cheon, Soyoung& Kim, Dong Yeon& Cho, Dae Jin& Park, Jeong Min…[et al.]. Novel Application of Radotinib for the Treatment of Solid Tumors via Natural Killer Cell Activation. Journal of Immunology Research. 2018. Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1193339
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1193339